Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)

Launched by PETROV, ANDREY · Jan 31, 2025

Keywords

ClinConnect Summary

This is a pilot study to evaluate the efficacy of adding the mitochondrial oxidative phosphorylation inhibitor S-Gboxin (OXPHOS) to standard treatment for glioblastoma multiforme or glioma.

Subjects will start oral S-gboxin orally twice daily and will evaluate the patients and vital status if they tolerate this dose at 3, 7and 15 days after initiation.

Patients will undergo MRI scans before treatment and then at multiple time points during their participation in this Clinical Trial to monitor early tumor response to treatment ( MRI dates will be scheduled by the clinical trial coordinator...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • confirmed diagnosis of Glioblastoma according to RANO criteria by contrast-enhanced MRI or PET-CT (including diffuse midline glioma, gliosarcoma or giant cell glioblastoma), relapse or disease progression
• • patient is able to understand and give consent to participate in the study
• • Karnofsky performance score ≥ 60
• • women of childbearing potential must have a negative pregnancy test result no later than 7 days before registration
• Exclusion Criteria:
• • pregnant
• • known allergies
• • active treatment on annotner clinical trial
• • inability to complete with protocol or studio procedures.